Positron Corporation Secures $8 Million in Capital to Accelerate Growth and Market Expansion
Positron (POSC) has secured an $8 million equity investment through the sale of 8 million common shares to two strategic investors. The capital will fund the company's expansion in the PET-CT imaging market, particularly in nuclear cardiology and oncology.
The funding will support multiple strategic initiatives, including:
- Enhanced sales and marketing efforts
- Expansion of sales personnel
- Product development and offerings
- Strengthening industry partnerships
- Market expansion in North America and Europe
The company plans to use this capital to resume SEC filings and pursue an uplisting to a senior stock exchange. According to President Adel Abdullah, this investment positions Positron to capitalize on increasing PET-CT imaging adoption and develop a competitive edge in the marketplace.
Positron (POSC) ha ottenuto un investimento in equity di 8 milioni di dollari attraverso la vendita di 8 milioni di azioni comuni a due investitori strategici. Il capitale finanzierà l'espansione dell'azienda nel mercato dell'imaging PET-CT, in particolare nella cardiologia nucleare e nell'oncologia.
Il finanziamento supporterà molteplici iniziative strategiche, tra cui:
- Potenziare le vendite e le attività di marketing
- Espansione del personale di vendita
- Sviluppo e offerta di nuovi prodotti
- Rafforzamento delle partnership nel settore
- Espansione del mercato in Nord America e Europa
L'azienda prevede di utilizzare questo capitale per riprendere le registrazioni SEC e perseguire un uplisting su una borsa valori senior. Secondo il Presidente Adel Abdullah, questo investimento posiziona Positron per capitalizzare sull'aumento dell'adozione dell'imaging PET-CT e sviluppare un vantaggio competitivo nel mercato.
Positron (POSC) ha asegurado una inversión de capital de 8 millones de dólares mediante la venta de 8 millones de acciones comunes a dos inversores estratégicos. El capital financiará la expansión de la empresa en el mercado de imágenes PET-CT, particularmente en cardiología nuclear y oncología.
La financiación apoyará múltiples iniciativas estratégicas, incluyendo:
- Mejoras en las ventas y esfuerzos de marketing
- Expansión del personal de ventas
- Desarrollo y oferta de productos
- Fortalecimiento de las asociaciones en la industria
- Expansión del mercado en América del Norte y Europa
La empresa planea utilizar este capital para reanudar los registros en la SEC y buscar una cotización en una bolsa de valores superior. Según el presidente Adel Abdullah, esta inversión posiciona a Positron para capitalizar la creciente adopción de imágenes PET-CT y desarrollar una ventaja competitiva en el mercado.
포지트론 (POSC)는 두 명의 전략적 투자자에게 800만 달러의 자본을 확보하기 위해 800만 주의 보통주를 판매했습니다. 이 자본은 PET-CT 영상 시장에서의 회사의 확장을 지원할 것입니다. 특히 핵심 심장학 및 종양학 분야에서 활동할 예정입니다.
이 자금은 다음과 같은 여러 전략적 이니셔티브를 지원할 것입니다:
- 판매 및 마케팅 활동 강화
- 판매 인력 확장
- 제품 개발 및 제공
- 업계 파트너십 강화
- 북미 및 유럽 시장 확장
회사는 이 자본을 사용하여 SEC 등록을 재개하고 상장 거래소로의 업리스를 추구할 계획입니다. 아델 압둘라 회장에 따르면, 이 투자는 포지트론이 PET-CT 영상 채택 증가를 활용하고 시장에서 경쟁 우위를 개발하는 데 도움이 될 것입니다.
Positron (POSC) a sécurisé un investissement en capital de 8 millions de dollars grâce à la vente de 8 millions d'actions ordinaires à deux investisseurs stratégiques. Ce capital financera l'expansion de l'entreprise sur le marché de l'imagerie PET-CT, en particulier dans le domaine de la cardiologie nucléaire et de l'oncologie.
Le financement soutiendra plusieurs initiatives stratégiques, notamment :
- Renforcement des efforts de vente et de marketing
- Expansion du personnel de vente
- Développement et offre de produits
- Renforcement des partenariats industriels
- Expansion du marché en Amérique du Nord et en Europe
L'entreprise prévoit d'utiliser ce capital pour reprendre les dépôts auprès de la SEC et poursuivre une cotation sur une bourse supérieure. Selon le président Adel Abdullah, cet investissement positionne Positron pour tirer parti de l'adoption croissante de l'imagerie PET-CT et développer un avantage concurrentiel sur le marché.
Positron (POSC) hat eine Eigenkapitalinvestition von 8 Millionen Dollar durch den Verkauf von 8 Millionen Stammaktien an zwei strategische Investoren gesichert. Das Kapital wird die Expansion des Unternehmens im PET-CT-Bildgebungsmarkt finanzieren, insbesondere in der nuklearmedizinischen Kardiologie und Onkologie.
Die Finanzierung wird mehrere strategische Initiativen unterstützen, darunter:
- Verbesserte Verkaufs- und Marketingaktivitäten
- Erweiterung des Verkaufspersonals
- Produktentwicklung und -angebote
- Stärkung der Branchenpartnerschaften
- Marktexpansion in Nordamerika und Europa
Das Unternehmen plant, dieses Kapital zu nutzen, um die SEC-Registrierungen wieder aufzunehmen und eine Notierung an einer höheren Börse anzustreben. Laut Präsident Adel Abdullah positioniert diese Investition Positron, um von der steigenden Akzeptanz der PET-CT-Bildgebung zu profitieren und einen Wettbewerbsvorteil im Markt zu entwickeln.
- Secured $8 million in equity funding
- Plans to uplist to a senior stock exchange
- Strategic expansion into European markets
- Resuming SEC filings to improve transparency
- No debt incurred in the capital raise
- 8 million new shares issued, causing dilution for existing shareholders
Niagara Falls, NY, March 31, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT imaging systems and clinical support services, is pleased to announce it has secured
This investment will enable Positron to advance its strategic initiatives, including sales and marketing efforts and sales personnel, enhancing its current and future product offerings and further solidifying its partnerships within the nuclear medical imaging industry. The Company anticipates this capital to drive Positron’s advancement of the PET modality, strengthen its presence in North America and support future expansion to European markets. Additionally, it will be a significant foundation for the Company to resume SEC filings and move toward uplisting on a senior stock exchange.
Additionally, this capital raise aligns with Positron’s long-term vision of collaborating with current and future strategic alliances, enhancing its technology portfolio, and expanding its global footprint. The Company remains committed to driving innovation in molecular imaging and ensuring that more healthcare providers have access to the most advanced diagnostic tools available.
Adel Abdullah, President of Positron, stated, "Positron is now well positioned to expand and reinforce its leading role in the PET-CT imaging industry," Mr. Abdullah added, "The demand for PET is just at the beginning of significant adoption stemming from an unprecedented industry shift towards the superior modality and performance of PET-CT imaging. We expect this capital to accelerate customer acquisitions, enter new markets, introduce new products and develop a competitive edge in the marketplace. We believe Positron will play a key role in the future advancement of the PET modality.”
ABOUT POSITRON CORPORATION
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
FORWARD-LOOKING STATEMENTS
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Some of the risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; and new product introductions by our competitors. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
FAQ
How much capital did Positron (POSC) raise in March 2025?
What will POSC use the $8 million investment for?
How many shares did Positron (POSC) issue in the March 2025 funding round?
What markets is Positron (POSC) planning to expand into with the new funding?
What is Positron 's (POSC) plan for stock exchange listing?
